Bristol-Myers Squibb Company (NYSE: BMY) is now fully own MyoKardia after it has finalized the buying process. BMY has bought MyoKardia Inc. in an all-cash deal for nearly $13.1 billion. After this deal, Bristol-Myers will get mavacamten which is the cardiovascular drug used to treat obstructive hypertrophic cardiomyopathy (HCM).

The firm is preparing to submit the New Drug Application (NDA) for mavacamten to FDA in the Q121. After the completion of the acquisition, the shares of MyoKardia have stopped trading on the NASDAQ Global Select Market. Previously, BMY has declared the tender offer for all outstanding shares of common stock of MyoKardia for $225.00 per share terminated at the end of the day on November 16, 2020.

Bristol-Myers Squibb Company (BMY) has seen some recent movement in the stock market and its common shares are trading at $64.13. Traders are starting to take notice of BMY as the common shares trading as high as $64.70 and as low as $63.88 at the time the article was written.

Bristol-Myers Squibb Company (BMY) average trading volume is 10.24M. However, in today’s market session Bristol-Myers Squibb Company (BMY) exchanged 3,833,321 shares till now. The First support level on BMY is $63.65 and the First upside resistance level on BMY is $65.67. BMY 50day moving average is $61.01 and BMY 200day moving average is $60.34.

Bristol-Myers Squibb Company (BMY) recent performance has been indicated by the recent movement in BMY common shares. BMY has performed 5.32% over the past 4 weeks, BMY has performed 2.33% over the past 90 days and BMY has shown 10.09% over the past 1 year. Bristol-Myers Squibb Company (BMY) has a 52 week range of $45.76 to $68.34. Bristol-Myers Squibb Company (BMY) is trading 40.37% from its 52 week low and -6.01% from its 52 week high. Bristol-Myers Squibb Company (BMY) is showing a 0.70% short float showing the sum short in the float.

BMY has 2.26B shares outstanding and 2.26B shares in the float. Bristol-Myers Squibb Company (BMY) currently has a market cap of $143.76B and an income of -44.00M. The EPS next quarter for BMY is 1.41 and the projected EPS next year is 16.82%. The market cap of Bristol-Myers Squibb Company (BMY) at $143.76B represents how many Traders own shares of BMY and is calculated off the last price ($64.13) of BMY and the sum of shares outstanding (2.26B) with Bristol-Myers Squibb Company (BMY).

Bristol-Myers Squibb Company (BMY) has aggregate cash (mrq) of 21.28B, aggregate cash per share (mrq) of 9.42, aggregate debt of BMY is at 45.81B and aggregate debt/equity (mrq) is 91.20. . Bristol-Myers Squibb Company (BMY) operating cash flow (ttm) is 12.42B, BMY leveraged free cash flow (ttm) is 14.97B.

BMY is trading 4.39% above (bullish) its SMA20, 6.28% above (bullish) its SMA50 and 7.08% above (bullish) its SMA200.